Results 11 to 20 of about 46,310 (42)

Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease [PDF]

open access: yes, 2012
Background: Uremic solute concentration increases as Glomerular Filtration Rate (GFR) declines. Weak associations were demonstrated between estimated GFR (eGFR) and the concentrations of several small water-soluble and protein-bound uremic solutes ...
Barreto, Daniela V   +9 more
core   +5 more sources

RAGs and Regulation of Autoantibodies [PDF]

open access: yes, 2004
Autoreactive antibodies are etiologic agents in a number of autoimmune diseases. Like all other antibodies these antibodies are produced in developing B cells by V(D)J recombination in the bone marrow.
Casellas, Rafael   +4 more
core   +1 more source

The antibody loci of the domestic goat (Capra hircus) [PDF]

open access: yes, 2018
The domestic goat (Capra hircus) is an important ruminant species both as a source of antibody-based reagents for research and biomedical applications and as an economically important animal for agriculture, particularly for developing nations that ...
Bickhart, Derek M.   +4 more
core   +1 more source

Structural insights and biomedical potential of IgNAR scaffolds from sharks [PDF]

open access: yes, 2014
Peer reviewedPublisher ...
Barelle, Caroline   +5 more
core   +1 more source

Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury. a Case Series [PDF]

open access: yes, 2018
Background/Aims: Multiple myeloma (MM) represents 10% of all haematologic malignancies. Renal involvement occurs in 50% of MM patients; of them, 12-20% have acute kidney injury (AKI), with 10% needing dialysis at presentation. While hemodialysis (HD) has
Antolino, Giusy   +7 more
core   +2 more sources

INDEPENDENT SYNTHESIS OF LIGHT AND HEAVY CHAINS : Quantitation of Light-Chain Production by Mouse Myeloma Variants [PDF]

open access: yes, 1974
The rates of immunoglobulin synthesis have been examined in two MFC-11 cell lines which were independently adapted to tissue culture and in light-chain-producing variants derived from each of them.
Laskov, Reuven, Scharff, Matthew D.
core   +1 more source

IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design [PDF]

open access: yes, 2017
Rodent monoclonal antibodies with specificity towards important biological targets are developed for therapeutic use by a process of humanisation. This process involves the creation of molecules, which retain the specificity of the rodent antibody but ...
Angal   +34 more
core   +1 more source

The Solution Structures of Two Human IgG1 Antibodies Show Conformational Stability and Accommodate Their C1q and FcγR Ligands. [PDF]

open access: yes, 2015
The human IgG1 antibody subclass shows distinct properties compared with the IgG2, IgG3, and IgG4 subclasses and is the most exploited subclass in therapeutic antibodies. It is the most abundant subclass, has a half-life as long as that of IgG2 and IgG4,
Abe   +79 more
core   +1 more source

Non-functional immunoglobulin G transcripts in a case of hyper-immunoglobulin M syndrome similar to type 4 [PDF]

open access: yes, 2004
86% of immunoglobulin G (IgG) heavy-chain gene transcripts were found to be non-functional in the peripheral blood B cells of a patient initially diagnosed with common variable immunodeficiency, who later developed raised IgM, whereas no non-functionally
Allen RC   +9 more
core   +3 more sources

Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. [PDF]

open access: yes, 1988
Recently the minor B cell subpopulation that expresses the CD5 (Leu-1) antigen has been implicated as a source of IgM autoantibodies. Chronic lymphocytic leukemia (CLL), the most common leukemia in humans, represents a malignancy of small B lymphocytes ...
Carson, DA   +3 more
core  

Home - About - Disclaimer - Privacy